Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review.
Primary immune thrombocytopenia is a potentially life-threatening condition. Approximately two-thirds of adult patients do not have a sustained response to steroids (first-line therapy). For these patients, a number of other treatment options exist, such as rituximab, splenectomy, immunosuppressants, and thrombopoietin receptor agonists, but they are costly and have side effects. Dapsone is an inexpensive drug with a well-established safety profile. Unfortunately, this treatment option has not been explored adequately. This review is aimed at analyzing the currently available evidence for the use of dapsone as second-line or third-line therapy in primary immune thrombocytopenia.
Department of Clinical Medicine, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
C
C
Rodrigo
L
L
Gooneratne
D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003622:Dapsone / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy*; D053628:Receptors, Thrombopoietin / Q000819:agonists; D000069283:Rituximab; D013156:Splenectomy; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D053628:Receptors, Thrombopoietin; D000069283:Rituximab; D003622:Dapsone
Immune Thrombocytopenic Purpura; cost; dapsone; rituximab; splenectomy; treatment